◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › Z › ZYME

Zymeworks Inc. Common Stock (ZYME) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-06

Zymeworks Inc. Common Stock (ZYME) operates in the BIOTECHNOLOGY industry and is headquartered in Middletown, United States with about 231 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, ZYME reported $106M in revenue and ($81M) in net income.

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases.

Interactive charts & full statements → Open the ZYME valuation workbench →

ZYME Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31
Total Revenue	$37M	$106M	$76M	$76M	$412M	$27M	$39M	$30M	$53M	$52M	$11M	$10M	$2M
Gross Profit	$33M	$106M	$76M	($67M)	$412M	$27M	$39M	($88M)	$53M	$11M	($25M)	($15M)	($9M)
Gross Margin %	87.8%	100.0%	100.0%	-88.1%	100.0%	100.0%	100.0%	-296.3%	100.0%	20.5%	-222.9%	-152.6%	-527.1%
Operating Income (EBIT)	($156M)	($93M)	($137M)	($138M)	$131M	($216M)	($187M)	($151M)	($33M)	($9M)	($38M)	($20M)	($13M)
Operating Margin %	-419.0%	-87.3%	-179.7%	-181.6%	31.6%	-808.2%	-481.3%	-512.1%	-62.5%	-17.4%	-343.9%	-206.6%	-763.4%
Net Income	($150M)	($81M)	($123M)	($119M)	$124M	($212M)	($181M)	($145M)	($37M)	($10M)	($34M)	($19M)	($13M)
Net Margin %	-404.0%	-76.6%	-160.8%	-156.1%	30.1%	-794.0%	-463.5%	-492.3%	-69.0%	-20.1%	-307.1%	-198.4%	-775.0%
EBITDA	($140M)	($69M)	($109M)	($121M)	$143M	($206M)	($177M)	($148M)	($29M)	($6M)	($36M)	($19M)	($12M)
Earnings Per Share (EPS)	$-2.01	$-1.08	$-1.62	$-1.72	$1.91	$-4.06	$-3.58	$-3.83	$-1.26	$-0.49	$-1.72	$-0.97	$-0.65
Shares Outstanding (M)	73M	75M	76M	69M	65M	52M	50M	38M	29M	21M	20M	20M	20M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ZYME Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$5M	$2M	$3M	$28M	$49M	$27M	$31M	$16M
Gross Profit	$5M	$0M	$1M	$28M	$49M	$27M	$31M	$16M
Gross Margin %	100.0%	-18.2%	32.8%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	($42M)	($47M)	($44M)	($22M)	($1M)	($26M)	($22M)	($34M)
Operating Margin %	-919.0%	-1956.7%	-1755.5%	-80.1%	-1.4%	-94.5%	-71.6%	-213.8%
Net Income	($45M)	($44M)	($41M)	($20M)	$2M	($23M)	($24M)	($30M)
Net Margin %	-980.8%	-1834.0%	-1638.5%	-71.0%	4.8%	-83.5%	-75.8%	-186.6%
EBITDA	($43M)	($41M)	($40M)	($16M)	$3M	($22M)	($19M)	($32M)
Earnings Per Share (EPS)	$-0.62	$-0.59	$-0.55	$-0.26	$0.03	$-0.30	$-0.31	$-0.39
Shares Outstanding (M)	73M	75M	75M	76M	77M	75M	76M	76M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ZYME Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31
Cash from Operations (CFO)	($119M)	($33M)	($110M)	($118M)	$144M	($192M)	($151M)	($82M)	$24M	$0M	($35M)	($22M)	($7M)
Capital Expenditures (CapEx)	$1M	$2M	$3M	$4M	$13M	$13M	$6M	$14M	$3M	$3M	$5M	$1M	$0M
Free Cash Flow (FCF)	($120M)	($35M)	($113M)	($122M)	$131M	($206M)	($158M)	($96M)	$21M	($3M)	($41M)	($23M)	($7M)
FCF Margin %	-324.5%	-32.6%	-148.2%	-161.0%	31.8%	-771.1%	-404.8%	-324.0%	39.1%	-5.6%	-369.8%	-238.3%	-437.0%
Dividends Paid	—	—	—	$814M	—	—	$1M	$1M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ZYME Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($32M)	($46M)	($10M)	($31M)	$12M	($3M)	($42M)	($6M)
Capital Expenditures (CapEx)	$0M	$0M	$1M	$0M	$1M	$0M	$0M	$1M
Free Cash Flow (FCF)	($32M)	($46M)	($11M)	($32M)	$11M	($4M)	($42M)	($7M)
FCF Margin %	-700.7%	-1907.6%	-419.6%	-115.2%	23.0%	-13.8%	-134.8%	-42.9%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ZYME Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31
Total Assets	$397M	$347M	$463M	$581M	$649M	$389M	$538M	$368M	$244M	$132M	$94M	$23M	$51M
Cash & Cash Equivalents	$179M	$41M	$66M	$158M	$401M	$202M	$242M	$128M	$42M	$36M	$16M	$12M	$47M
Total Liabilities	$317M	$78M	$124M	$116M	$156M	$140M	$128M	$123M	$64M	$16M	$85M	$5M	$11M
Total Debt (Short + Long-Term)	$3M	$3M	$3M	$4M	$3M	$1M	$3M	$1M	$0M	$0M	$4M	$0M	$0M
Total Shareholders' Equity	$80M	$269M	$339M	$465M	$493M	$249M	$410M	$246M	($145M)	$116M	$9M	$18M	$40M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ZYME viewer.

Other Companies in BIOTECHNOLOGY

MESO · Mesoblast Ltd — $2 billion
RAPP · Rapport Therapeutics, Inc. Common Stock — $2 billion
GHRS · GH Research PLC — $2 billion
COAG · Hemab Therapeutics Holdings, Inc. Common Stock — $2 billion
FTRE · Fortrea Holdings Inc. — $2 billion
XNCR · Xencor Inc — $2 billion
STOK · Stoke Therapeutics Inc — $2 billion
SEPN · Septerna, Inc. Common Stock — $2 billion

← ZYDUSWELL All “Z” companies

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.